Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 telehealth prescribing for addiction
Telehealth firms are offering off-label GLP-1 drugs for addiction. Two semaglutide trials show a signal, but not approval or class-wide proof.
Why we wrote this. Telehealth marketing is moving faster than indication-specific evidence. We mapped the claims to two randomized trials and kept their populations intact.
In this article (8 sections)
Telehealth companies are marketing off-label GLP-1 prescriptions for alcohol use disorder and other addictions before FDA approval for those uses, according to STAT[1]. The clinical evidence for semaglutide in alcohol use disorder has moved beyond anecdotes, but it is still early and diagnosis-specific. Two randomized trials do not validate broad prescribing for every substance use disorder.
What telehealth platforms are offering
STAT reports that a few telehealth companies began marketing branded and compounded GLP-1 drugs for alcohol use disorder and other addictions during the past year. The reporting frames the concern as fragmented care and a shift of evidence-vetting onto patients. Addiction treatment can involve withdrawal risk and psychiatric symptoms. Other medicines and social support needs may also escape a narrow prescription visit.
Off-label prescribing is not the same as FDA approval for a new indication. A licensed clinician may prescribe an approved drug for a use outside its label, but the agency has not concluded that the drug is safe and effective for that use. Compounded products add another distinction because they are not FDA-approved versions of the branded medicine.
The first randomized signal was small
A 2025 phase 2 trial randomized 48 adults with alcohol use disorder to nine weeks of once-weekly semaglutide or placebo. Participants were not seeking treatment. Semaglutide reduced alcohol consumed during a laboratory self-administration task and reduced drinks per drinking day and weekly craving. It did not change average drinks per calendar day or the number of drinking days[2].
The study offers prospective evidence, but its size and setting restrict the conclusion. Forty-eight participants at one academic center cannot establish effectiveness across routine addiction care. The brief treatment window does not answer durability or relapse after discontinuation. It also cannot detect rare harms or show how the medicine compares with approved alcohol-use-disorder treatments.
These results provide an early signal without establishing a treatment standard. The laboratory endpoint measured drinking under controlled conditions after participants had received a low dose, while the outpatient measures relied on behavior across the study period. A larger trial can confirm an effect and still leave practical questions unresolved, including which patients are likely to respond and whether reduced craving leads to fewer medical, family, or work consequences over time.
A 2026 trial added stronger evidence
A 26-week randomized, double-blind trial enrolled 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. The semaglutide group had a 41.1-percentage-point reduction from baseline in heavy drinking days versus 26.4 points with placebo, an estimated between-group difference of 13.7 percentage points[3].
Eighty-eight participants completed the intervention. Gastrointestinal adverse events were more frequent with semaglutide and were described in the abstract as transient and generally mild to moderate. Every participant had obesity as well as alcohol use disorder, and the trial studied semaglutide alongside cognitive behavioral therapy. It did not test a prescription-only telehealth model.
What the trials do not establish
Neither trial supports a class-wide claim that any GLP-1 drug treats any addiction. Alcohol use disorder is not interchangeable with opioid, cocaine, methamphetamine, gambling, or nicotine disorders. Drugs in the incretin class also differ in receptor activity, formulation, dose range, and available safety data. Evidence for one molecule and one diagnosis should stay attached to that molecule and diagnosis.
The trials also do not show that compounded semaglutide has the same evidence as an approved branded product. They did not evaluate common telehealth workflows, asynchronous screening, or fragmented records. A company can market access faster than researchers can define who benefits, who is exposed to avoidable risk, and what monitoring is needed.
Why fragmented care is a clinical issue
Alcohol use disorder ranges in severity. Abrupt reduction can carry withdrawal risk for some people, and co-occurring depression or anxiety may affect immediate safety. A clinician needs an accurate alcohol history, current medicines, medical conditions, and a plan for follow-up. A GLP-1 prescription does not replace withdrawal assessment, behavioral treatment, or access to established addiction medicines.
Readers considering the evidence should separate the investigational addiction use from approved metabolic uses and review the semaglutide regulation record. Marketing language such as craving control can sound broader than the measured endpoints. In the 2025 trial, some outcomes changed and others did not. In the 2026 trial, the enrolled population had both obesity and alcohol use disorder.
What to ask before accepting a prescription
Patients can ask which diagnosis is being treated, whether the product is FDA-approved or compounded, what evidence applies to their condition, and how the clinician will coordinate with existing care. They can also ask what happens if drinking changes quickly, which adverse effects require attention, and how outcomes will be assessed. Those questions do not resolve the evidence gap, but they make the scope of care visible.
What we do not yet know
Larger multisite trials need to define durability, uncommon harms, treatment discontinuation, and comparative effectiveness. Researchers also need to test whether any benefit extends beyond alcohol use disorder and beyond patients with obesity. Until those results exist, semaglutide for addiction remains an off-label clinical decision, not an FDA-approved addiction treatment or a substitute for full addiction care.
Medical disclaimer
This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Is semaglutide FDA-approved for alcohol use disorder?
No. The cited randomized trials studied an investigational use. FDA approval for diabetes or weight management does not create approval for alcohol use disorder.
Do GLP-1 drugs treat every addiction?
That has not been shown. The strongest cited randomized evidence concerns semaglutide in alcohol use disorder. It cannot be extended automatically to other GLP-1 drugs or other substance and behavioral disorders.
What did the larger alcohol trial find?
In 108 adults with alcohol use disorder and obesity, semaglutide plus cognitive behavioral therapy reduced heavy drinking days more than placebo plus therapy over 26 weeks. The estimated between-group difference was 13.7 percentage points.
Sources
- [1]STAT: Telehealth off-label GLP-1 prescriptions for addictionTier 2 · expert↩
- [2]Hendershot et al. Once-Weekly Semaglutide in Adults With Alcohol Use DisorderTier 1 · primary↩
- [3]Klausen et al. Semaglutide versus placebo in alcohol use disorder and obesityTier 1 · primary↩
No revisions yet. First published .